These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 14238721)
1. THE DISORDERED MOVEMENT IN PARKINSONISM AND THE EFFECT OF DRUG TREATMENT. DRAPER IT; JOHNS RJ Bull Johns Hopkins Hosp; 1964 Dec; 115():465-80. PubMed ID: 14238721 [No Abstract] [Full Text] [Related]
4. A COMPARATIVE STUDY OF TRIHEXYPHENIDYL (ARTANE) AND ORPHENADRINE (DISIPAL) IN THE TREATMENT OF GERIATRIC PARKINSONISM. STRANG RR J Am Geriatr Soc; 1965 Aug; 13():756-9. PubMed ID: 14322547 [No Abstract] [Full Text] [Related]
6. ORPHENADRINE IN THE TREATMENT OF PARKINSON'S DISEASE. STRANG RR Curr Med Drugs; 1964 Sep; 5(1):24-31. PubMed ID: 14179566 [No Abstract] [Full Text] [Related]
7. Antiparkinsonism drugs. Med Lett Drugs Ther; 1965 Mar; 7(6):22-4. PubMed ID: 5831354 [No Abstract] [Full Text] [Related]
8. TREATMENT OF DRUG-INDUCED PARKINSONISM: A COMPARISON BETWEEN UK-738, ORPHENADRINE, AND A PLACEBO IN A DOUBLE BLIND STUDY. JENSEN K; AMDISEN A Psychopharmacologia; 1964 Mar; 5():301-5. PubMed ID: 14143342 [No Abstract] [Full Text] [Related]
9. INTERCHANGEABLITY OF ANTIPARKINSONIAN MEDICATION. STJEAN A; DONALD M; BAN TA Am J Psychiatry; 1964 Jun; 120():1189-90. PubMed ID: 14154754 [No Abstract] [Full Text] [Related]
10. DRUGS FOR PARKINSONISM. RICHARDSON JC Can Med Assoc J; 1965 Apr; 92(17):928-9. PubMed ID: 14289143 [No Abstract] [Full Text] [Related]
11. THE EFFECTS OF BIPERIDEN HYDROCHLORIDE (AKINETON) IN POST-ENCEPHALITIC PARKINSONISM. MILLER V Scott Med J; 1964 Sep; 9():391-3. PubMed ID: 14200166 [No Abstract] [Full Text] [Related]
12. BEHAVIORAL EFFECTS OF INTERACTING IMIPRAMINE AND OTHER DRUGS WITH D-AMPHETAMINE, COCAINE, AND TETRABENAZINE. SCHECKEL CL; BOFF E Psychopharmacologia; 1964 Feb; 5():198-208. PubMed ID: 14138755 [No Abstract] [Full Text] [Related]
13. CURRENT VIEWS CONCERNING THE ETIOLOGY, PATHOPHYSIOLOGY, AND TREATMENT OF PARKINSON'S DISEASE. MEYER JS; MAGEE KR J Neuropsychiatr; 1964 Jun; 5():284-90. PubMed ID: 14167691 [No Abstract] [Full Text] [Related]
14. Assessment of drug therapy in Parkinsonism. ONUAGULUCHI G Br Med J; 1963 Feb; 1(5328):443-8. PubMed ID: 13940177 [No Abstract] [Full Text] [Related]
15. THE IMPORTANCE OF LIPID-SOLUBILITY FOR THE CENTRAL ACTION OF CHOLINOLYTIC DRUGS. HERZ A; TESCHEMACHER H; HOFSTETTER A; KURZ H Int J Neuropharmacol; 1965 Jul; 4():207-18. PubMed ID: 14343875 [No Abstract] [Full Text] [Related]
16. A clinical assessment of orphenadrine (disipal) in the treatment of Parkinsonism. ROBINSON LR; DICK TH Ulster Med J; 1960 Jun; 29(1):64-9. PubMed ID: 14437972 [No Abstract] [Full Text] [Related]
17. SOME REMARKS ON THE TREATMENT OF POST-ENCEPHALITIC OCULOGYRIC CRISES WITH BENZTROPINE METHANESULFONATE. PAULSON G; BUFFALOE WJ Int J Neuropsychiatry; 1965; 1():214-5. PubMed ID: 14309084 [No Abstract] [Full Text] [Related]
19. Effects of amantadine and of some synthetic antiparkinsonian drugs on the behavioral response to L-DOPA in mice. Florio V; Longo VG Physiol Behav; 1971 Apr; 6(4):465-6. PubMed ID: 5148760 [No Abstract] [Full Text] [Related]
20. [CONTRIBUTION TO THE THERAPY AND REHABILITATION OF PARKINSON'S SYNDROME]. GERSTENBRAND F; PATEISKY K Wien Z Nervenheilkd Grenzgeb; 1963 May; 21():124-31. PubMed ID: 14078450 [No Abstract] [Full Text] [Related] [Next] [New Search]